Tandem Diabetes Care (TNDM) Revenue (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Revenue for 14 consecutive years, with $254.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 5.77% year-over-year to $254.6 million; the trailing twelve-month figure through Jun 2026 stood at $1.0 billion (up 3.96% YoY), and the FY2025 full-year result was $1.0 billion, up 7.93% from the prior year.
• Revenue advanced to $254.6 million in Q2 2026 per TNDM's latest filing, from $247.2 million in the prior quarter.
• Across five years, Revenue topped out at $290.4 million in Q4 2025 and bottomed at $169.4 million in Q1 2023.
• Historically, Revenue has averaged $222.5 million across 5 years, with a median of $221.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Revenue fell 10.75% in 2023, then jumped 43.62% in 2024.
• Over 5 years, Revenue stood at $220.5 million in 2022, then declined by 10.75% to $196.8 million in 2023, then soared by 43.62% to $282.6 million in 2024, then rose by 2.74% to $290.4 million in 2025, then decreased by 12.34% to $254.6 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $254.6 million, $247.2 million, and $290.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.